サイクリン依存キナーゼ12は,内臓リーシュマニアの薬標的である
Susan Wyllie1, Michael Thomas1, Stephen Patterson1
1Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
Nature
|July 27, 2018
まとめ
CRK12を標的とした新しい抗リーシュマニア薬が有望です ピラゾロピリミジンベースの化合物は,臨床前モデルで有効であり,内臓リーシュマニアの新たな治療法を提供している.
科学分野:
- 薬剤化学
- 寄生虫学
- 薬物の発見
背景:
- 内臓リーシュマニア症 (VL) は,高い死亡率と罹患率を持つ重症な寄生虫性疾患である.
- 現存するVL治療は限られており 毒性や耐性などの課題に直面しています
- VLに対する新しい効果的な治療薬の必要性が非常に高いのです
研究 の 目的:
- 新種の抗リーシュマニア薬を開発する
- 臨床開発の可能性のある鉛化合物を特定する.
- 新しい抗リーシュマニア化合物の作用機構を明らかにする.
主な方法:
- ピラゾロピリミジン化学系の設計と合成
- 腸内リーシュマニア症のマウスモデルでのin vivo有効性試験
- 鉛化合物の薬物動態,物理化学,および毒性分析
- 分子標的を特定するための作用形態の研究
主要な成果:
- ピラゾロピリミジン基の抗リーシュマニア化合物の新しいシリーズが開発された.
- 鉛化合物 (7,DDD853651/ GSK3186899) は,VLの臨床前マウスモデルで有効性を示した.
- 鉛化合物は薬のような好ましい性質を持ち,臨床前候補として提唱されています.
- このシリーズの化合物は,寄生虫のcdc- 2関連キナーゼ12 (CRK12) を抑制することが判明した.
結論:
- ピラゾロピリミジンシリーズは,有望な抗リーシュマニア剤の新種を代表しています.
- CRK12の抑制は,内臓リーシュマニア症の治療に有効な薬剤標的として特定されています.
- 鉛化合物は,新しいVL治療へのさらなる開発のための強力な候補です.
関連する概念動画
Drug Dependence
1.7K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.7K
cAMP-dependent Protein Kinase Pathways
8.5K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.5K
Protein Kinases and Phosphatases
15.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases
4.5K
4.5K
Targets for Drug Action: Overview
10.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.4K
Receptor Tyrosine Kinases
18.9K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.9K


